Page last updated: 2024-12-09

2-(1,3-benzoxazol-2-ylthio)-N-(6-bromo-1,3-benzothiazol-2-yl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(1,3-benzoxazol-2-ylthio)-N-(6-bromo-1,3-benzothiazol-2-yl)acetamide is a **complex organic molecule** that combines features from both benzoxazole and benzothiazole rings. This specific structure is not widely known or researched, and there isn't readily available information on its importance or specific applications.

**Here's why it's difficult to find information about this specific compound:**

* **Novelty:** It might be a recently synthesized compound, not yet widely investigated or reported in the scientific literature.
* **Specificity:** The compound's precise structure and potential properties could make it relevant to a very specific research field, limiting its broader recognition.
* **Limited Research:** There might not be much research dedicated to this particular compound due to lack of funding, interest, or availability.

**Potential Research Significance:**

While information on this compound is limited, it's possible that it could hold interest for research due to its structural features:

* **Benzoxazole and Benzothiazole Motifs:** These heterocyclic rings are commonly found in molecules with pharmacological activity, particularly in areas like:
* **Antibacterial and antifungal agents:** Both benzoxazoles and benzothiazoles have been explored for their potential in combating infections.
* **Anti-inflammatory and analgesic compounds:** These ring systems often contribute to pain-relieving and anti-inflammatory properties.
* **Cancer treatment:** Some benzoxazole and benzothiazole derivatives exhibit promising activity against cancer cells.
* **Bromo Substitution:** The bromine atom on the benzothiazole ring could influence the compound's properties, potentially enhancing its activity or affecting its binding to biological targets.
* **Thiourea Linkage:** The thioamide group (C=S-NH) present in the molecule could contribute to its activity, as thioamides are often associated with biological activity.

**To determine the importance of this compound for research, more information is needed.**

**Here's what you can do:**

* **Search scientific databases:** Explore databases like PubChem, SciFinder, and Google Scholar using the compound's full name or specific keywords related to its structure.
* **Contact experts:** Reach out to researchers specializing in organic synthesis, medicinal chemistry, or related fields to inquire about the compound's potential.

It's important to remember that without more information about the compound's synthesis, activity, or potential applications, it's challenging to assess its significance for research.

Cross-References

ID SourceID
PubMed CID2352842
CHEMBL ID1533951
CHEBI ID111300

Synonyms (12)

Synonym
OPREA1_525119
smr000154741
MLS000568583
CHEBI:111300
MLS002633213
AKOS001306879
2-(1,3-benzoxazol-2-ylsulfanyl)-n-(6-bromo-1,3-benzothiazol-2-yl)acetamide
HMS2284I16
Z19651021
CHEMBL1533951
2-(1,3-benzoxazol-2-ylthio)-n-(6-bromo-1,3-benzothiazol-2-yl)acetamide
Q27190917
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoxazoleCompounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency10.00000.002014.677939.8107AID1476
TDP1 proteinHomo sapiens (human)Potency18.35640.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency1.41250.180013.557439.8107AID1460
Smad3Homo sapiens (human)Potency5.62340.00527.809829.0929AID588855
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency39.81070.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency44.66840.035520.977089.1251AID504332
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
DNA polymerase betaHomo sapiens (human)Potency89.12510.022421.010289.1251AID485314
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency75.68630.425612.059128.1838AID504891
DNA polymerase eta isoform 1Homo sapiens (human)Potency39.81070.100028.9256213.3130AID588591
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glycogen synthase kinase-3 alphaHomo sapiens (human)AC50300.00000.013529.7434171.7000AID463203
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]